Summary
The aims of the study were twofold: (1) to evaluate the effect of food on the relative oral bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine the absolute bioavailability of oral topotecan with reference to the intravenous (i.v.) formulation. The study had a randomized two-period cross-over design. On day 1 of the first treatment course patients were administered 2.3 mg m–2 day–1 of oral topotecan with or without a high-fat breakfast. They crossed over to receive the alternate regimen on day 2. In the second course (3 weeks later) fasted patients received topotecan orally (2.3 mg m–2 day–1) or i.v. (1.5 mg m–3 day). They crossed over to receive the alternate regimen on day 2. On days 3–5 of both treatment courses patients received oral topotecan. Plasma pharmacokinetics were performed on days 1 and 2 of the first and second course using a high-performance liquid chromatographic assay. Eighteen patients were enrolled in the study. The ratio of the area under the curve to infinity during fasted and high-fat treatment was 0.93 ± 0.23 (90% confidence interval (CI) 0.83–1.03). Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6 ± 4.4 ng ml–1) or without food (9.2 ± 4.1 ng ml–1) (P = 0.130). The time needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8–6.1) compared to fasted conditions (2.0 h, range 1.1–8.1) (P = 0.013). The absolute bioavailability of topotecan averaged 42 ± 13% (90% CI 37– 47%). The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9 ± 1.0 h) than after i.v. administration (2.7 ± 0.4 h) (P < 0.001). Topotecan demonstrates suitable bioavailability for oral treatment. Co-administration of the topotecan gelatin capsules with a high-fat breakfast leads to a small decrease in absorption rate but does not affect the extent of absorption.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ajani, J. A., Welch, S. R., Raber, M. N., Fields, W. S. & Krakoff, I. H. (1990). Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147–159.
Burris, HAIII, Hanauske, A. R., Johnson, R. K., Marshall, M. H., Kuhn, J. G., Hilsenbeck, S. G. & Von Hoff, D. D. (1992). Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 84: 1816–1820.
Creemers, G. J., Gerrits, C. J. H., Eckardt, J. R., Schellens, J. H. M., Burris, H. A., Planting, A. S. T., Rodriguez, G. I., Loos, W. J., Hudson, I., Broom, C., Verweij, J. & Von Hoff, D. D. (1997). Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15: 1087–1093.
Committee for Proprietary Medicinal Products (1992). Note for Guidance: Investigation of Bioavailability and Bioequivalence (III/54/89-EN), CPMP: Brussels
Davies, B. E., Minthorn, E. A., Dennis, M., Beijnen, J. H. & Rosing, H. (1995). The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Eur J Cancer 31A: S28
Eckardt, J., Burris, H., Rizzo, J., Fields, S., Rodrigues, G., DelaCruz, P., Hodges, S., Von, Hoff & Kuhn, J. (1995). A phase I safety and bioavailability study of oral topotecan. Eur J Cancer 31A: S193
Gerrits, C. J. H., Burris, H., Schellens, J. H. M., Planting, A. S. T., Van der Burg, M. E. L., Rodrigues, G. I., Van Beurden, V., Loos, W. J., Hudson, I., Fields, S., Verweij, J. & Von Hoff, D. D. (1998). Five days of oral topotecan (Hycamtin®), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 7: 34
Herben, V. M. M., Ten Bokkel Huinink, W. W., Dubbelman, A. C., Mandjes, I. A. M., Groot, Y., Van Zomeren, D. M. & Beijnen, J. H. (1997). Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide. Br J Cancer 76: 1500–1508.
Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K. & Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715–720.
Houghton, P. J., Cheshire, P. J., Hallman, JDII, Lutz, L., Friedman, H. S., Danks, M. K. & Houghton, J. A. (1995). Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393–403.
Hsiang, Y-H & Liu, L. F. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726.
Hsiang, Y-H, Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R. & Potmesil, M. (1989). DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res 49: 4385–4389.
Marzo, A. & Balant, L. P. (1995). Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneim-Forsch/Drug Res 45: 109–115.
Pabst, G. & Jaeger, H. (1990). Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Cancer 38: 5–10.
Pommier, Y., Jaxel, C., Kerrigan, D. & Kohn, K. W. (1991). Structure–activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In DNA Topoisomerases in Cancer, Potmesil M, Kohn KW Oxford University Press: New York 121–132.
Rosing, H., Doyle, E., Davies, B. E. & Beijnen, J. H. (1995). High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 668: 107–111.
Rosing, H., Herben, V. M. M., Van Gortel-van Zomeren, D. M., Hop, E., Kettenes-van den Bosch, J. J., Ten Bokkel Huinink, W. W. & Beijnen, J. H. (1997). Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 39: 498–504.
Schellens, J. H. M., Creemers, G. J., Beijnen, J. H., Rosing, H., De Boer-Dennert, M., McDonald, M., Davies, B. & Verweij, J. (1996). Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73: 1268–1271.
Supko, J. G., Plowman, J., Dyker, D. J. & Zaharko, D. S. (1992). Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33: 432
Underberg, W. J. M., Goossen, R. M. J., Smith, B. R. & Beijnen, J. H. (1990). Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8: 681–683.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Herben, V., Rosing, H., Huinink, W. et al. Oral topotecan: bioavailability and effect of food co-administration. Br J Cancer 80, 1380–1386 (1999). https://doi.org/10.1038/sj.bjc.6690532
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690532
Keywords
This article is cited by
-
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
Nature Reviews Clinical Oncology (2016)
-
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Cancer Cell International (2015)
-
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
British Journal of Cancer (2015)
-
Oral Anticancer Drugs: Mechanisms of Low Bioavailability and Strategies for Improvement
Clinical Pharmacokinetics (2013)
-
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer
Cancer Chemotherapy and Pharmacology (2013)
